Alvotech Highlighted 52wk. Study Results of AVT04 (biosimilar, ustekinumab) for Chronic Plaque Psoriasis
Shots:
- The 52wk. study evaluating the safety, efficacy, tolerability, immunogenicity, and PK b/w AVT04 and originator ustekinumab in a ratio (1:2) in patients with mod. to sev. chronic PsO
- The results showed the therapeutic equivalence b/w AVT04 and reference ustekinumab. The study met its 1EPs & showed PASI improvement was 87.3% vs 86.8% & the incidence of Abs to ustekinumab had no clinically meaningful impact, the proportion of patients who achieved PASI50, PASI75, PASI90, and PASI100 before and after switching was similar across treatment arms with no clinically significant differences
- 34.5% vs 33.6% experienced TEAEs. Ustekinumab, an interleukin-12 (IL-12) and IL-23 inhibitor was approved to treat a variety of inflammatory diseases, incl. PsO
Ref: HCL Live | Image: Alvotech
Related News:- Alvotech and Teva Settled with Johnson & Johnson for AVT04, a Proposed Biosimilar to Stelara (ustekinumab)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
